

GSK Issued: Monday 1 February 2010, London UK

Update on GSK contributions to Haiti relief

The first wave of medicines donated by GlaxoSmithKline, valued at \$1.6 million, has been utilized rapidly for first line treatment of those affected by the earthquake in Haiti. Medicines have been provided from stocks held in the warehouses of our non-profit partners, such as [AmeriCares](#), [Direct Relief International](#), [Health Partners International of Canada](#), [IMA \(International Medical Assistance\)](#), [MAP International](#) and [Project Hope](#).

Following specific requests to support primary healthcare needs in the medium to longer-term, GSK has donated significant volumes of antibiotics as well as respiratory and diabetes treatments, valued at \$10 million. Additionally, GSK's consumer division has provided a range of consumer products, including toothpastes, antacids, pain relievers and vitamins.

Last week, the company made a cash donation of approximately \$408,000 (£250,000) to the British Red Cross to help meet the water and sanitation needs of those affected by the disaster. A Mass Sanitation Unit has arrived in Haiti with the British Red Cross emergency team. This will support up to 20,000 displaced people by constructing 200 emergency latrines and distribution of essential hygiene kits. It is estimated that the provision of water and sanitation facilities can significantly reduce infections and mortality rates following a disaster.

In addition to providing product donations and financial support, we are proud of the contributions of our GSK employees currently working in the PULSE program, who have taken on additional responsibilities to support emergency response partners working on the front line of the relief efforts.

We are committed to providing whatever we can in response to the huge needs emerging in Haiti and will continue to review requests from our established partners.

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com